Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/34293
Title: Prognostic Markers within the Tumour Microenvironment in Classical Hodgkin Lymphoma.
Austin Authors: Martynchyk, Arina;Chowdhury, Rakin;Hawkes, Eliza A ;Keane, Colm
Affiliation: Olivia Newton-John Cancer Wellness and Research Centre
Princess Alexandra Hospital, 199 Ipswich Rd., Woolloongabba, QLD 4102, Australia.;Frazer Institute, University of Queensland, St. Lucia, QLD 4072, Australia.
School of Public Health & Preventive Medicine, Monash University, 553 St Kilda Rd., Melbourne, VIC 3004, Australia.
Princess Alexandra Hospital, 199 Ipswich Rd., Woolloongabba, QLD 4102, Australia.;Frazer Institute, University of Queensland, St. Lucia, QLD 4072, Australia.
Issue Date: 30-Oct-2023
Date: 2023
Publication information: Cancers 2023-10-30; 15(21)
Abstract: Classical Hodgkin lymphoma (cHL) accounts for 0.4% of all new cancer cases globally. Despite high cure rates with standard treatment, approximately 15% of patients still experience relapsed or refractory (RR) disease, and many of these eventually die from lymphoma-related causes. Exciting new targeted agents such as anti-PD-1 agents and brentuximab vedotin have changed the therapeutic paradigm beyond chemotherapy and radiotherapy alone. Advances in understanding of the molecular biology are providing insights in the context of novel therapies. The signature histology of cHL requires the presence of scant malignant Hodgkin Reed-Sternberg cells (HRSCs) surrounded by a complex immune-rich tumour microenvironment (TME). The TME cellular composition strongly influences outcomes, yet knowledge of the precise characteristics of TME cells and their interactions with HRSCs is evolving. Novel high-throughput technologies and single-cell sequencing allow deeper analyses of the TME and mechanisms elicited by HRSCs to propagate growth and avoid immune response. In this review, we explore the evolution of knowledge on the prognostic role of immune cells within the TME and provide an up-to-date overview of emerging prognostic data on cHL from new technologies that are starting to unwind the complexity of the cHL TME and provide translational insights into how to improve therapy in the clinic.
URI: https://ahro.austin.org.au/austinjspui/handle/1/34293
DOI: 10.3390/cancers15215217
ORCID: 
Journal: Cancers
PubMed URL: 37958391
Type: Journal Article
Subjects: Classical Hodgkin lymphoma
PD-L1
T-cells
immune checkpoint inhibitors
prognostic markers
tumour microenvironment
tumour-associated macrophages
Appears in Collections:Journal articles

Show full item record

Page view(s)

36
checked on Apr 19, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.